You are here
Pharmacological Treatment of Insomnia
People experience two forms of sleep: rapid eye movement (REM) and nonrapid eye movement (NREM). Sleep typically begins with the NREM phase, which is followed by the REM phase. NREM sleep is subdivided into three stages in which brain activity, eye movement, and skeletal muscle tone progressively decrease, placing the individual in a deeper state of sleep. Later in the cycle, when the individual enters REM sleep, electrical activity in the brain increases, contributing to increased blood flow to the brain, changes in respiratory and cardiac rates, and dreaming.1 REM sleep correlates with activities of the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system in healthy humans.2
Sleep is regulated by a variety of chemicals in the body. In the forebrain and hypothalamus, neurons release gamma-aminobutyric acid (GABA) and histamine. These neurotransmitters have opposing actions on the sleep–wake cycle. Increased GABA and decreased histamine release induce NREM sleep by deactivating the cortex and thalamus. The sleep–wake cycle is also affected by neurotransmitters released by reticular activating system (RAS) neurons, such as norepinephrine, acetylcholine, and serotonin. These neurotransmitters contribute to maintaining wakefulness and significantly decrease during REM sleep. Orexin, which is produced in the hypothalamus, is a neuropeptide that plays an important role in maintaining wakefulness. It is hypothesized that the action of orexin changes the activity of the neurotransmitters involved in the regulation of sleep/wake states. Melatonin is a hormone that plays an integral role in diurnal rhythms. It synchronizes the body with the environment’s light–dark cycle, peaking during the night and dipping during the day, to stabilize the body’s natural circadian rhythm.1,3
According to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), insomnia is defined as dissatisfaction with sleep quantity or quality that results in clinically significant distress or impairment in social, occupational, or other important areas of functioning. Insomnia is associated with one or more of the following symptoms: difficulty initiating sleep (sleep-onset insomnia or initial insomnia); difficulty maintaining sleep (sleep-maintenance insomnia or middle insomnia); and early-morning awakening with the inability to return to sleep (late insomnia).4
An estimated 50 million to 70 million adults in the U.S. have chronic sleep and wakefulness disorders.5 Insomnia is more common in women (25%) than in men (18%), and its prevalence increases with age, affecting approximately 50% of the elderly population.6 Data from the years 2008 through 2010 from the National Health Interview Survey indicated that 62% of adults in the U.S. slept seven to eight hours and that 28% slept six or fewer hours in a 24-hour period.7 In the National Health and Nutrition Examination Survey (2005–2010), approximately 4% of U.S. adults 20 years of age and older reported that they had taken prescription sleep aids during the previous 30 days.8
Investigators have characterized insomnia as a disorder of hyperarousal that manifests as hypervigilance during the day and difficulty initiating and maintaining sleep at night.9–11 This hyperarousal may result from chronic activation of the neuroendocrine system’s stress response. Studies have found high levels of urinary free cortisol in poor sleepers.12 Moreover, high levels of both cortisol and adrenocorticotropic hormone (ACTH) in insomniacs suggest that the HPA axis is associated with the pathology of chronic insomnia.13 Dysregulation of corticotropin-releasing factor (CRF) has also been implicated in the mediation of hyperarousal seen in primary insomnia.14
Several comorbid medical conditions can contribute to insomnia. These include obstructive sleep apnea, fibromyalgia, restless legs syndrome, cardiovascular diseases, diabetes, arthritis, migraine, asthma, chronic obstructive pulmonary disease, and chronic pain.1,13,15,16
Insomnia consists of three basic types: acute insomnia, primary chronic insomnia, and associated insomnia.13 Acute insomnia results from a triggering causal factor that is easily identifiable in an individual who has not had insomnia before. By definition, the acute form does not last longer than four months.17
Primary chronic insomnia may be caused by several predisposing (genetic and constitutional) factors, including hyperactivity of stress response mechanisms or of the HPA axis; anxiety and depression; and abnormalities in the circadian rhythm (circadian sleep-wakefulness control).12,14,17–19 Precipitating and perpetuating factors, such as psychosocial features (e.g., fatigue and irritability), behavioral changes, and cognitive characteristics, also contribute to insomnia.13
Associated insomnia is primarily related to an underlying mental or mood disorder, such as depression, dysthymia, cyclothymia, bipolar disorder, anxiety, or schizophrenia.17,20–23 This form of insomnia may also be caused by inadequate sleep hygiene (i.e., habits that are inappropriate for good quality of sleep), such as psychologically stressful activities; the consumption of caffeine, nicotine, alcohol, or heavy meals; or vigorous physical activity near bedtime.17 Other potential causes of associated insomnia include concomitant medical conditions (e.g., infections and metabolic diseases) and the use of substances or medications (e.g., alcohol, stimulants, and antidepressants).17
The Centers for Disease Control and Prevention further classifies insomnia as episodic (lasting at least one month but less than three months); persistent (lasting three months or longer); or recurrent (two or more episodes within one year).24
To qualify for a diagnosis of insomnia, patients must have at least one of the following complaints for at least three nights per week: difficulty initiating and/or maintaining sleep; sleep that is poor in quality; trouble sleeping despite adequate opportunity and circumstances for sleep; or waking up too early.17,24 In addition, patients must have at least one of the following types of daytime impairment related to sleep difficulty: attention, concentration, or memory impairment; concerns or worries about sleep; daytime sleepiness; errors or accidents at work or while driving; fatigue or malaise; gastrointestinal symptoms; lack of motivation; mood disturbance or irritability; social or vocational dysfunction or poor school performance; or tension headaches.17
Regardless of the type of therapy used, the treatment of chronic insomnia has two primary objectives: improving sleep quality and quantity, and improving daytime impairments. Initial approaches to treatment usually include at least one behavioral intervention, such as stimulus control therapy or relaxation therapy. Biofeedback therapy is also used. When pharmacotherapy is required, the choice of a specific drug within a class should be directed by: 1) symptom pattern; 2) treatment goals; 3) past treatment responses; 4) patient preference; 5) cost; 6) the availability of other treatments; 7) comorbid conditions; 8) contraindications; 9) concurrent medication interactions; and 10) potential adverse effects. 25
The recommended sequence of medication trials is:25
- Short- or intermediate-acting benzodiazepine receptor agonists (BzRAs) or the melatonin agonist ramelteon.
- Alternative short- or intermediate-acting BzRAs or ramelteon if the initial agent was ineffective.
- Sedating antidepressants (e.g., trazodone, amitriptyline, doxepin, or mirtazapine).
- The combination of a BzRA or ramelteon with a sedating antidepressant.
- Other sedating agents, such as antiepilepsy medications or atypical antipsychotics.
In the following sections, we will discuss prescription medications approved by the Food and Drug Administration (FDA), off-label treatments, over-the-counter drugs, and herbal therapies for patients with insomnia.
BENZODIAZEPINE RECEPTOR AGONISTS
BzRAs include both benzodiazepine (BZD) and non-BZD agents. Although all of these drugs bind to the gamma aminobutyric acid (GABAA) receptor complex, they differ in their affinity for binding sites. BZDs have similar selectivity for alpha subunits 1, 2, 3, and 5, whereas non-BZDs bind more selectively to the alpha 1 subunit. The various subunits of the GABAA receptors are responsible for the sedative–hypnotic, muscle-relaxant, anxiolytic, and anticonvulsant effects of the BzRAs. Moreover, the selectivity of non-BZDs for the alpha 1 subunit is believed to result in fewer adverse effects on the central nervous system (CNS) and in a reduced potential for abuse compared with BZDs.26
Currently, five BZDs are FDA-approved for the treatment of insomnia: triazolam (Halcion, Pfizer), estazolam (ProSom, Abbott), temazepam (Restoril, Mallinckrodt), quazepam (Doral, Questcor), and flurazepam. All of these agents are Schedule IV controlled substances because of their potential for abuse or dependence. The primary difference among them is their duration of action. Triazolam is short-acting; estazolam and temazepam are intermediate-acting; and quazepam and flurazepam are long-acting. Temazepam is the most commonly prescribed BZD for insomnia. The choice of a BZD should be based on the desired onset and duration of action. Patients have developed rapid tolerance to the sedative effects of BZDs; therefore, long-term use of these drugs is not recommended.27
In a meta-analysis of 45 randomized controlled trials, BZDs decreased sleep latency and significantly improved total sleep duration in more than 2,600 subjects. All of the studies, however, were of short duration (14 days or less), which prevented the investigators from analyzing tolerance to the drugs’ hypnotic properties.28
In addition to the potential for tolerance and dependence, BZDs have been associated with psychomotor retardation, memory impairment, paradoxical inhibition (e.g., increased excitement, irritability, and impulsivity), depression, and teratogenic effects in pregnant women.29 BZDs should be avoided in elderly patients because of the potential for cognitive impairment, delirium, falls, and fractures.30
Non-BZDs, also called “Z drugs,” were developed to minimize the adverse effects and abuse potential associated with BZDs. A meta-analysis of 13 studies involving more than 4,000 subjects showed that the currently available Z drugs—zolpidem, zaleplon, and eszopiclone—provided small but statistically significant reductions in subjective and polysomnographic sleep latency compared with placebo. The degree to which sleep latency was reduced was greater in studies involving larger doses, longer treatment durations, and greater proportions of younger and/or female patients.31
Zolpidem was the first Z drug to be developed. It is currently available as immediate- and modified-release tablets (Ambien and Ambien CR, respectively [both Sanofi]); as sublingual tablets (Edluar [Meda Pharmaceuticals] and Intermezzo [Transcept Pharmaceuticals]); and as an oral spray (ZolpiMist, NovaDel Pharma). In studies comparing the pharmacokinetics of the zolpidem sublingual tablets and oral spray with that of immediate-release zolpidem tablets, the sublingual formulations maintained bioequivalence while offering a shorter onset of action.32,33 Treatment costs should be considered, since some zolpidem formulations are available only as brand-name products.
In studies of zolpidem, treatment-emergent adverse events, such as drowsiness, nausea, dizziness, nightmares, and agitation, have resulted in discontinuation of the drug.34 Similar adverse-event profiles have been noted between controlled-release and immediate-release formulations.35 In clinical studies, zolpidem did not alter retrograde memory, a hallmark adverse effect of the older BZD treatments used for insomnia. However, anterograde amnesia was seen in some patients.36,37 Based on its pharmacokinetic profile (i.e., its extended half-life), greater effects on anterograde amnesia may be expected with controlled-release zolpidem.38
Drugs with CNS-depressant effects could potentially enhance the CNS-depressant effects of zolpidem. In addition, the coadministration of cytochrome P450 3A4 (CYP3A4) inhibitors may increase exposure to zolpidem. The drug should be used with caution in combination with imipramine, chlorpromazine, rifampin, or ketoconazole.39
In January 2013, the FDA recommended that clinicians use lower doses of zolpidem because new data had shown that blood levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving. The FDA informed the manufacturers that the recommended dose of zolpidem for women should be lowered from 10 mg to 5 mg for immediate-release products (Ambien, Edluar, and ZolpiMist) and from 12.5 mg to 6.25 mg for extended-release products (Ambien CR). The FDA also informed the manufacturers that, for men, the labeling should recommend that health care professionals consider prescribing the lower doses―5 mg for immediate-release products and 6.25 mg for extended-release products. The recommended doses of Intermezzo, a lower-dose zolpidem product approved for middle-of-the-night awakenings, did not change.40
Zaleplon (Sonata, Pfizer) was the second non-BZD to become available. Its rapid onset of action and significantly shorter duration of action offer advantages for patients with middle-of-the-night awakenings.41 In a randomized, double-blind, placebo-controlled study, both zaleplon and zolpidem effectively shortened sleep latency and lengthened sleep duration when administered during nighttime awakening. The duration of residual sedation, however, was shorter with zaleplon than with zolpidem.42
Headache and dizziness were the most common adverse events in clinical studies of zaleplon. The percentages of patients who withdrew from these studies because of adverse events were similar between the zaleplon and placebo groups.43,44
Unlike the other non-BZDs, which are extensively metabolized by CYP3A4, zaleplon is primarily metabolized by aldehyde oxidase. Although the coadministration of potent CYP3A4 inhibitors and inducers may alter zaleplon levels, routine dosage adjustments are not usually required.45
The absorption of zaleplon is delayed by approximately two hours and is reduced by 35% if the drug is taken with high-fat or heavy meals. Zaleplon is a pregnancy category C drug and should be used with caution in pregnant women. The typical dosing range for nonelderly adults is 10 mg to 20 mg. A 5-mg dose is recommended for specific populations, such as older, debilitated, or hepatically impaired patients. Zaleplon is not recommended for patients with severe hepatic impairment.45
Eszopiclone (Lunesta, Sunovion) is a non-BZD hypnotic agent approved for the long-term treatment of insomnia.46 A six-month, double-blind, placebo-controlled, parallel-group study of approximately 800 patients demonstrated that eszopiclone was effective for the treatment of insomnia as measured by sleep latency, total sleep time, and wake time after sleep onset.47 Because of its longer half-life, eszopiclone should be used only in patients who can have at least seven to eight hours of sleep before the planned time of awakening.46
The adverse events most commonly observed with eszopiclone include an unpleasant taste, headache, somnolence, and dizziness.48,49 In a six-week study of patients with primary insomnia, there was no evidence of tolerance to eszopiclone during therapy or of rebound insomnia after the drug was discontinued.49
Eszopiclone is primarily metabolized by CYP3A4. Concurrent use of potent inhibitors or inducers of CYP3A4 enzymes may affect exposure to the drug. Dose reductions are recommended in patients receiving eszopiclone along with a potent CYP3A4 inhibitor, such as ketoconazole. The use of eszopiclone with CYP3A4 inducers, such as rifampin, may reduce its efficacy.46
Eszopiclone is absorbed rapidly, with a time to peak concentration of approximately one hour. Taking eszopiclone with or immediately after a heavy meal results in slower absorption and a subsequent reduction in the drug’s effect on sleep onset. Eszopiclone is FDA pregnancy category C and should be used with caution in pregnant women. Nonelderly adults may take a maximum dose of 3 mg if clinically indicated. The dose should not exceed 2 mg in patients taking potent CYP3A4 inhibitors or in special populations, such as older, debilitated, or hepatically impaired patients.46,50
In May 2014, the FDA issued a warning regarding next-day impairment of driving and other activities after the use of eszopiclone. As a result, the recommended starting dose was reduced to 1 mg at bedtime.51
MELATONIN AGONIST: RAMELTEON
Ramelteon (Rozerem, Takeda) is approved for the treatment of insomnia characterized by difficulty with sleep onset, and it is the only melatonin (MT) agonist with this indication.52 As a targeted MT1 and MT2 receptor agonist, ramelteon does not have an affinity for GABA receptors, which negates the potential for abuse.53 Studies have shown that ramelteon is effective in reducing both polysomnographic and subjective sleep latency in patients with chronic insomnia.54–57
The most common ramelteon-related adverse events include dizziness, nausea, and fatigue.52,58 Unlike zolpidem and eszopiclone, ramelteon does not affect patients’ balance, thereby reducing the risk of falls. In addition, the drug is not associated with cognitive or psychomotor effects.59
Although ramelteon is absorbed rapidly, it has limited bioavailability as a result of extensive first-pass metabolism. The absorption of ramelteon is delayed and reduced when it is taken with food. Because of its short half-life (1.36 hours), ramelteon should not be used to treat patients with difficulty maintaining sleep.52
Ramelteon is metabolized by several CYP enzymes. The combination of ramelteon and fluvoxamine, a potent CYP1A2 inhibitor, should be avoided. Moreover, ramelteon should be used with caution in patients taking potent CYP3A4 inhibitors, such as ketoconazole, or potent CYP2C9 inhibitors, such as fluconazole. The use of ramelteon with potent CYP3A4 inducers, such as rifampin, may reduce its efficacy.52
Ramelteon is a pregnancy category C drug and should be used with caution in pregnant women. Although the drug is cleared more slowly from older adults compared with younger ones, with a 70% greater area under the curve (AUC), no dose adjustments are required in the elderly. Ramelteon should be used with caution in patients with mild-to-moderate hepatic impairment and is contraindicated in those with severe hepatic impairment.52
TRICYCLIC ANTIDEPRESSANT: DOXEPIN
Doxepin (Silenor, Pernix Therapeutics) is a sedating tricyclic antidepressant (TCA) with a high affinity for histamine (H1) receptors. It is approved for the treatment of insomnia characterized by difficulty with sleep maintenance.60
Headache and somnolence are the most common adverse events associated with doxepin. Minimal to no adverse effects are reported with the lower doses approved for sleep compared with the higher doses used for depression.60 A review of nine randomized, placebo-controlled studies found that low-dose doxepin provided modest improvements in sleep maintenance and sleep duration but had no effect on sleep initiation. No significant residual (next-day) sedative effects were reported.61 In a four-week, randomized, double-blind, placebo-controlled study involving 254 elderly subjects, treatment with doxepin resulted in improved sleep time and fewer awakenings after sleep onset without causing anticholinergic adverse events or memory impairment.62
The absorption of doxepin is increased by approximately 40% and the time to peak plasma concentration is delayed by approximately three hours when the drug is taken after a high-fat meal. For that reason, doxepin should not be administered within three hours after eating.60
Doxepin is a pregnancy category C drug and should be used with caution in pregnant women. It is extensively metabolized by CYP2C19 and CYP2D6. Therefore, concomitant use of doxepin with inhibitors of these enzymes may increase drug exposure. The dosage for nonelderly adults is 6 mg taken 30 minutes before bedtime. The initial dose in older patients is 3 mg, which may be titrated to 6 mg if clinically indicated. The dose should not exceed 3 mg in patients with hepatic impairment.60
The CNS depression achieved with barbiturates can range from mild sedation to general anesthesia. In addition, hypnotic doses of these drugs can decrease sleep latency and the number of awakenings.26,63 As a class, barbiturates are FDA-approved for the treatment of patients with insomnia. They are not recommended for use in that setting, however, because of their significant adverse effects, including the potential for fatal overdose, their low therapeutic index, and the potential for tolerance and dependence.25
OREXIN RECEPTOR ANTAGONIST: SUVOREXANT
Suvorexant (Belsomra, Merck) is the first marketed drug in a new category of insomnia medications known as orexin receptor antagonists. Orexins are neurotransmitters that regulate wakefulness and sleep. Suvorexant was approved in August 2014 for the treatment of insomnia characterized by difficulty with sleep onset and/or sleep maintenance. It is a Schedule IV controlled substance.64,65
A 12-month, randomized, placebo-controlled, parallel-group trial evaluated suvorexant in subjects with primary insomnia. Suvorexant (n = 517) showed greater efficacy than placebo (n = 254) in improving subjective total sleep time (38.7 minutes versus 16.0 minutes, respectively; P < 0.0001) and subjective time to sleep onset (−18.0 minutes versus −8.4 minutes; P = 0.0002). The most common adverse event, somnolence, occurred in 13% of the suvorexant group and in 3% of the placebo group.66
The recommended starting dosage for suvorexant in insomnia patients is 10 mg administered once per night within 30 minutes of going to bed. The dose may be increased to a maximum of 20 mg as tolerated. The drug should be administered no later than seven hours before the planned time of awakening.65
Suvorexant is a pregnancy category C drug. Dose adjustments are not necessary in patients with hepatic or renal impairment. No clinically significant differences in safety and efficacy have been observed in individuals more than 65 years of age compared with younger, healthy subjects. Suvorexant is mainly metabolized by the CYP3A enzyme; therefore, concomitant use with strong CYP3A inhibitors is contraindicated. These drugs can significantly decrease suvorexant levels, thus reducing the drug’s efficacy. When used with moderate CYP3A inhibitors, the initial dose of suvorexant should be reduced to 5 mg, which may be increased to 10 mg as tolerated.65
Based on clinical trial data and on the drug’s mechanism of action, the potential for abuse and adverse events may be lower with suvorexant than with BzRAs. The higher cost of suvorexant and the availability of less-expensive generic options, however, will likely hinder its widespread use. 67
OFF-LABEL TREATMENTS FOR INSOMNIA
Approved by the FDA more than 30 years ago, trazodone is used to treat depression at high doses. However, because of its modulating effect on serotonin (5-HTA) receptors, the drug is also used off-label as a hypnotic at low doses. Studies have shown that trazodone inhibits approximately 50% of the 5-HTA receptors in the brain at doses as low as 10 mg. In patients with insomnia, a starting dose of 25 to 50 mg at bedtime is recommended. This may be titrated to a dosage of 100 mg per night as indicated. Higher doses may result in anticholinergic adverse effects and orthostatic hypotension, which, in turn, may increase the risk of falls and resulting injury.68
Mirtazapine (Remeron, Merck), a member of the piperazinoazepine group of compounds, has sedative properties that may benefit patients with insomnia. Sedation is achieved through the drug’s potent antagonistic effects on histamine (H1) receptors. Mirtazapine is currently approved only for the treatment of major depressive disorder.69 A dosage of 30 mg per day is typically used in insomnia patients; increasing doses may diminish the drug’s sleep-enhancing effects.70 Mirtazapine has been associated with anticholinergic effects and may negatively affect treatment with triglycerides.69
Doxepin is FDA-approved for the treatment of insomnia marked by difficulty with sleep maintenance, but other sedating TCAs (such as amitriptyline, nortriptyline, and imipramine) have been used off-label to treat insomnia patients. The broad neurotransmitter effects of these drugs, however, confer an increased risk for anticholinergic effects, orthostatic hypotension, and slowed cardiac conduction, and safer treatment options have diminished their usefulness. TCAs have been listed as potentially inappropriate for use in older adults.30
Although not FDA-approved for the treatment of insomnia patients, atypical antipsychotic medications, such as quetiapine, olanzapine, and risperidone, are commonly prescribed for sleep disorders. The sedation associated with these drugs results from their antagonistic effects on multiple neurotransmitter systems, particularly serotonin (5-HT2) and histamine (H1) receptors. Quetiapine is the most commonly prescribed antipsychotic for insomnia.71,72
Although the effects of antipsychotics on sleep have been studied in patients with comorbid conditions, such as depression and psychosis, they have not been evaluated in subjects with primary insomnia. Serious adverse events, such as metabolic syndrome and extrapyramidal effects, make these drugs less attractive than agents approved by the FDA for this indication.73
Because of their sedating properties, the first-generation antihistamines diphenhydramine and doxylamine are available over the counter as sleep aids. Diphenhydramine, for example, is contained in Benadryl, Unisom SleepGels, and others, and doxylamine is contained in Unisom Sleep Tabs.74 The clinical use of these agents as insomnia treatments lacks supporting data.75
A randomized, double-blind, crossover study demonstrated that tolerance quickly develops to the sedative effect of diphenhydramine. Fifteen healthy men (ages 18 to 50 years) received either diphenhydramine 50 mg or placebo twice a day for four days. Both objective and subjective measures of sleepiness showed significantly higher levels on day 1 for diphenhydramine compared with placebo. By day 4, however, levels of sleepiness achieved by diphenhydramine were indistinguishable from those associated with placebo. The subjects’ tolerance to diphenhydramine was complete by the end of three days of administration.76
In addition to the potential for rapid tolerance, studies have indicated that diphenhydramine and doxylamine are only minimally effective in inducing sleep, may reduce sleep quality, and may cause residual drowsiness. Therefore, the use of these drugs in insomnia patients is not recommended.77
Moreover, antihistamines are associated with potent anticholinergic effects, such as dry mouth, constipation, and confusion. Older individuals are particularly susceptible to these effects and should generally avoid the use of antihistamines.30
Melatonin, a pineal-gland hormone involved in sleep regulation,78 is available over the counter primarily as a nutritional supplement, but it is also used to treat insomnia related to secondary causes, such as jet lag and shift work.79
In a randomized, double-blind, placebo-controlled study, a prolonged-release formulation of melatonin was associated with improvements in sleep and daytime parameters, including sleep latency, sleep quality, and morning alertness, after three weeks of treatment in adults with primary insomnia. The improvements were maintained in a subset of patients who continued treatment for a total of six months.80
In another short-term (one week), randomized, double-blind, placebo-controlled investigation, a physiological dose of melatonin (0.3 mg) restored sleep efficiency (P < 0.0001) and elevated plasma melatonin levels (P < 0.0008) to normal in adults with insomnia. A pharmacological dose (3.0 mg) also improved sleep, but it induced hypothermia and caused plasma melatonin to remain elevated during the day.81
In general, however, the evidence suggests that melatonin is not effective in treating most primary sleep disorders with short-term use (four weeks or less).82 Because of the relative lack of robust efficacy and safety data, melatonin is not recommended for the treatment of chronic insomnia.25
Valerian, an herbal product consisting of the root of Valeriana officinalis, has been used to treat insomnia since ancient Greek and Roman times.83 It appears to interact with GABA-ergic neurotransmission, thereby producing a sedative effect.84
Although some studies have indicated that valerian is useful for the treatment of patients with insomnia, others have not.85–89 Interpretation of the available clinical data is complicated by small sample sizes, by the use of different amounts and sources of valerian, by the different outcomes measured, and by high withdrawal rates.83 Overall, the evidence for valerian as an insomnia treatment remains inconclusive,85 and it is not recommended for use in these patients.25
The herbal product kava, derived from a shrub (Piper methysticum) cultivated in the Pacific islands, appears to act on both GABA and BZD binding sites, resulting in sedative, anticonvulsive, antispasmodic, and central muscular-relaxant effects.90,91 Over-the-counter kava-containing products are used as alternative therapies for anxiety, stress, and restlessness—major causes of chronic insomnia.91 However, as with other herbal substances, kava is not recommended for the treatment of chronic insomnia because of the relative lack of clinical efficacy and safety data.25 In 2002, the FDA warned that severe liver injury may result from the use of kava-containing products.92
The FDA has approved an array of prescription medications for the treatment of insomnia, including BZD and non-BZD drugs, the melatonin agonist ramelteon, the sedating antidepressant doxepin, and the orexin receptor antagonist suvorexant. In addition, several agents approved for other indications, such as the antidepressants trazodone and mirtazapine, are used in this setting. Over-the-counter alternative therapies include antihistamines, melatonin, and the herbal products valerian and kava.
FDA-Approved Medications for the Treatment of Insomnia
||47–100||Sleep-onset and sleep-maintenance insomnia||
||Generic: 15 mg, $0.73; 30 mg, $2.92|
||3.5–18.4||Sleep-onset and sleep-maintenance insomnia||
||Brand: 15 mg, $24.98|
Generic: 15 mg, $0.73
||1.5–5.5||Sleep-onset and sleep-maintenance insomnia||
||Brand: 0.25 mg, $4.27|
Generic: 0.25 mg, $2.74
||10–24||Sleep-onset and sleep-maintenance insomnia||
||Generic: 1 mg, $0.89|
||39–73||Sleep-onset and sleep-maintenance insomnia||
||Brand: 15 mg, $4.60 |
Generic: 15 mg, $9.25 (split tablet for 7.5 mg)
||Brand: 5 mg and 10 mg, $17.42|
Generic: 5 mg and 10 mg, $4.57
||Brand: 10 mg, $8.23 |
Generic: 10 mg, $3.60
||6||Sleep-onset and sleep-maintenance insomnia||
||Brand: 1 mg, $14.90 |
Generic: 1 mg, $11.67
||Brand: 8 mg, $12.23|
||10–22||Sleep-onset and sleep-maintenance insomnia||
||Brand: 10 mg, $10.52|
||Brand: 6 mg, $12.62|
|Butabarbital (Butisol Sodium)||
||100||Short-term treatment of sleep-onset and sleep-maintenance insomnia||
||Brand: 50 mg, $5.91 |
Generic: 50 mg, $5.91; 100 mg, $11.82
|Secobarbital (Seconal Sodium)||
||15–40||Short-term treatment of sleep-onset and sleep-maintenance insomnia||
||Brand: 100 mg, $38.53|
||8–17||Sleep-onset and sleep-maintenance insomnia||
||Brand: Two 25-mg tablets, $0.30 |
Generic: 50 mg, $0.03
|Doxylamine (Unisom SleepTabs)||
||10–12||Sleep-onset and sleep-maintenance insomnia||
*Average wholesale price per Red Book Online as of October 15, 2015
ADR = adverse drug reaction; CI = contraindicated; CYP = cytochrome P450
- Benca RM, Cirelli C, Tononi G. Basic science of sleep. In: Sadock BJ, Sadock VA, Ruiz P. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry
9th edPhiladelphia, Pennsylvania: Lippincott Williams & Wilkins. 2009;362–375.
- Vgontzas AN, Bixler EO, Papanicolaou DA, et al. Rapid eye movement sleep correlates with the overall activities of the hypothalamic-pituitary-adrenal axis and sympathetic system in healthy humans. J Clin Endocrinol Metab 1997;82:3278–3280.
- Siegel JM. The neurotransmitters of sleep. J Clin Psychiatry 2004;65;(suppl 16):4–7.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders
5th edArlington, Virginia: American Psychiatric Association. 2013;Available at: http://dsm.psychiatry-online.org/doi/full/10.1176/appi.books.9780890425596.dsm12. Accessed August 1, 2015
- Centers for Disease Control and Prevention. Unhealthy sleep-related behaviors: 12 states, 2009. Morbid Mortal Wkly Rep 2009;60:233–238.
- Budhiraja R, Roth T, Hudgel DW, et al. Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders. Sleep 2011;34:859–867.
- Centers for Disease Control and Prevention. Health Behaviors of Adults: United States, 2008–2010 Hyattsville, Maryland: U.S. Department of Health and Human Services. May 2013;Available at: https://www.cdc.gov/nchs/data/series/sr_10/sr10_257.pdf. Accessed September 4, 2015
- Chong Y, Fryar CD, Gu Q. Prescription Sleep Aid Use Among Adults: United States, 2005–2010 NCHS Data Brief No. 127Hyattsville, Maryland: National Center for Health Statistics. 2013;
- Yang CM, Lin SC, Cheng CP. Transient insomnia versus chronic insomnia: a comparison study of sleep-related psychological/behavioral characteristics. J Clin Psychol 2013;69:1094–1107.
- Stepanski E, Zorick F, Roehrs T, et al. daytime alertness in patients with chronic insomnia compared with asymptomatic control subjects. Sleep 1988;11:54–60.
- Bonnet MH, Arand DL. 24-hour metabolic rate in insomniacs and matched normal sleepers. Sleep 1995;18:581–588.
- Vgontzas AN, Bixler EO, Lin HM, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab 2001;86:3787–3794.
- Pinto Jr LR, Alves RC, Fontenelle J, et al. New guidelines for diagnosis and treatment of insomnia. Arq Neuropsiquiatr 2010;68:666–675.
- Roth T, Roehrs T, Pies R. Insomnia: pathophysiology and implications for treatment. Sleep Med Rev 2007;11:71–79.
- Arroll B, Fernando A, Falloon K, et al. Prevalence of causes of insomnia in primary care: a cross-sectional study. Br J Gen Pract 2012;62:e99–e103.
- Pearson NJ, Johnson LL, Nahin RL. Insomnia, trouble sleeping, and complementary and alternative medicine: analysis of the 2002 National Health Interview Survey data. Arch Intern Med 2006;166:1775–1782.
- American Academy of Sleep Medicine. International Classification of Sleep Disorders: Diagnostic and Coding Manual
2nd edWestchester, Illinois: American Academy of Sleep Medicine. 2005;
- Espie CA. Understanding insomnia through cognitive modelling. Sleep Med Rev 2007;8;(supp 4):S3–S8.
- Richardson GS. Human physiological models of insomnia. Sleep Med Rev 2007;8;(suppl 4):S9–S14.
- Buysse DJ, Angst J, Gamma A, et al. Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep 2008;31:473–480.
- Gregory AM, Caspi A, Eley TC, et al. Prospective longitudinal associations between persistent sleep problems in childhood and anxiety and depression disorders in adulthood. J Abnorm Child Psychol 2005;33:157–163.
- Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 2003;37:9–15.
- Riemann D, Voderholzer U. Primary insomnia: a risk factor to develop depression?. J Affect Disord 2003;76:255–259.
- Centers for Disease Control and Prevention. Key sleep disorders. July
12013;Available at: https://www.cdc.gov/sleep/about_sleep/key_disorders.htm. Accessed August 1, 2015
- Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008;4:487–504.
- Mihic S, Harris R. Hypnotics and sedatives. In: Brunton LL, Chabner BA, Knollmann BC, et al. Goodman & Gilman’s The Pharmacological Basis of Therapeutics
12th edChapter 17.New York, New York: McGraw-Hill. 2011;
- Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABA(A) receptor modulators?. Adv Pharmacol Sci 2012;2012:416864Available at: https://www.hindawi.com/journals/aps/2012/416864/. Accessed September 9, 2015.
- Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000;162:225–233.
- Longo LP, Johnson B. Addiction: part I. Benzodiazepines—side effects, abuse risk, and alternatives. Am Fam Physician 2000;61:2121–2128.
- American Geriatrics Society. Updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616–631.
- Huedo-Medina TB, Kirsch I, Middlemass J, et al. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ 2012;345:e8343
- Valente KD, Hasan R, Tavares SM, Gattaz WF. Lower doses of sublingual zolpidem are more effective than oral zolpidem to anticipate sleep onset in healthy volunteers. Sleep Med 2013;14:20–23.
- Neubauer DN. ZolpiMist: a new formulation of zolpidem tartrate for the short-term treatment of insomnia in the US. Nat Sci Sleep 2010;2:79–84.
- Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Int Clin Psychopharmacol 1998;13:157–167.
- Roth T, Soubrane C, Titeux L, Walsh JK. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006;7:397–406.
- Greenblatt DJ, Legangneux E, Harmatz JS, et al. Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 2006;46:1469–1480.
- Roehrs T, Merlotti L, Zorick F, Roth T. Sedative, memory, and performance effects of hypnotics. Psychopharmacology (Berl) 1994;116:130–134.
- Troy SM, Lucki I, Unruh MA, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol 2000;20:328–337.
- Ambien (zolpidem tartrate tablets) prescribing information Bridgewater, New Jersey: Sanofi-Aventis U.S. February 2008;Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019908s027lbl.pdf. Accessed September 9, 2015
- Food and Drug Administration. FDA drug safety communication: risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist) January
102013;Available at: https://www.fda.gov/drugs/drugsafety/ucm334033.htm. Accessed August 2, 2015
- Walsh JK, Coulouvrat C, Hajak G, et al. Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS). Sleep 2011;34:997–1011.
- Zammit GK, Corser B, Doghramji K, et al. Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening. J Clin Sleep Med 2006;2:417–423.
- Fry J, Scharf M, Mangano R, Fujimori M. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Int Clin Psychopharmacol 2000;15:141–52.
- Ebbens MM, Verster JC. Clinical evaluation of zaleplon in the treatment of insomnia. Nat Sci Sleep 2010;2:115–126.
- Sonata (zaleplon capsules) prescribing information Philadelphia, Pennsylvania: Wyeth Pharmaceuticals Inc.. May 2013;Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=710. Accessed September 9, 2015
- Lunesta (eszopiclone tablets) prescribing information Marlborough, Massachusetts: Sunovion Pharmaceuticals Inc.. May 2014;Available at: http://www.lunesta.com/PostedApprovedLabeling-Text.pdf. Accessed September 9, 2015
- Krystal AD, Huang H, Zummo J, et al. A WASO sub-group analysis of a 6-month study of eszopiclone 3 mg. Sleep Med 2012;13:691–696.
- Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005;6:487–495.
- Zammit GK, McNabb LJ, Caron J, et al. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20:1979–1991.
- Ancoli-Israel S, Krystal AD, McCall WV, et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep 2010;33:225–234.
- Food and Drug Administration. FDA drug safety communication: FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose May
152014;Available at:https://www.fda.gov/Drugs/DrugSafety/ucm397260.htm. Accessed August 2, 2015
- Rozerem (ramelteon tablets) prescribing information Deerfield, Illinois: Takeda Pharmaceuticals America Inc.. November 2010;Available at: https://general.takedapharm.com/legacy?filetypecode=rozerempi&cacheRandomizer=15ac1dc2-362c-4f72-b98a-5a334d7a2545. Accessed September 9, 2015
- Simpson D, Curran MP. Ramelteon: a review of its use in insomnia. Drugs 2008;68:1901–1919.
- Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007;3:495–504.
- Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007;23:1005–1014.
- Mini LJ, Wang-Weigand S, Zhang J. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. Am J Geriatr Pharmacother 2007;5:177–184.
- Wang-Weigand S, Mayer G, Roth-Schechter B. Long-term efficacy and safety of ramelteon 8 mg treatment in adults with chronic insomnia: results of a six-month, double-blind, placebo-controlled, polysomnography trial. Sleep Biol Rhythms 2007;5;(suppl 1):A156Abstract PO525.
- Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17–24.
- Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006;63:1149–1157.
- Silenor (doxepin tablets) prescribing information Morristown, New Jersey: Pernix Therapeutics. March 2010;Available at: https://www.silenor.com/Content/pdf/prescribing-information.pdf. Accessed September 9, 2015
- Yeung WF, Chung KF, Yung KP, Ng TH. Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep Med Rev 2015;19:75–83.
- Lankford A, Rogowski R, Essink B, et al. Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med 2012;13:133–138.
- Karacan I, Orr W, Roth T, et al. Dose-related effects of phenobarbitone on human sleep-waking patterns. Br J Clin Pharmacol 1981;12:303–313.
- Food and Drug Administration. FDA approves new type of sleep drug, Belsomra. August
182014;Available at: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm409950.htm. Accessed August 29, 2015
- Belsomra (suvorexant tablets) prescribing information White-house Station, New Jersey: Merck & Co., Inc.. August 2014;Available at: https://www.merck.com/product/usa/pi_circulars/b/belsomra/belsomra_pi.pdf. Accessed September 10, 2015
- Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13:461–471.
- Patel KV, Aspesi AV, Evoy KE. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia. Ann Pharmacother 2015;49:477–483.
- Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 2009;14:536–546.
- Remeron (mirtazapine tablets) prescribing information White-house Station, New Jersey: Merck & Co., Inc.. April 2015;Available at: http://www.merck.com/product/usa/pi_circulars/r/remeron/remeron_tablets_pi.pdf. Accessed September 10, 2015
- Poyurovsky M, Weizman R, Weizman A. Mirtazapine—a multifunctional drug: low dose for akathesia. CNS Spectr 2011;16:63
- Hermes ED, Sernyak M, Rosenheck R. Use of second-generation antipsychotic agents for sleep and sedation: a provider survey. Sleep 2013;36:597–600.
- Wiegand MH, Landry F, Brückner T, et al. Quetiapine in primary insomnia: a pilot study. Psychopharmacol (Berlin) 2008;196:337–338.
- Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf 2011;20:177–184.
- Mayo Clinic. Sleep aids: the options. November
202014;Available at: https://www.mayoclinic.org/healthy-lifestyle/adult-health/in-depth/sleep-aids/art-20047860?pg=2. Accessed September 10, 2015
- Vande Griend JP, Anderson SL. Histamine-1 receptor antagonism for treatment of insomnia. J Am Pharm Assoc 2012;52:e210–e219.
- Richardson GS, Roehrs TA, Rosenthal L, et al. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002;22:511–515.
- Ramakrishnan K, Scheid DC. Treatment options for insomnia. Am Fam Physician 2007;76:517–526.
- Buscemi N, Vandermeer B, Pandya R, et al. Melatonin for treatment of sleep disorders. Evid Rep Technol Assess (Summ) 2004;108:1–7.
- Almeida Montes LG, Ontiveros Uribe MP, Cortés Sotres J, et al. Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study. J Psychiatry Neurosci 2003;28:191–196.
- Wade AG, Ford I, Nir T, Zisapel N. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin 2011;27:87–98.
- Zhdanova IV, Wurtman RJ, Regan MM, et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001;86:4727–4730.
- Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders: a meta-analysis. J Gen Intern Med 2005;20:1151–1158.
- National Institutes of Health. Valerian: fact sheet for health professionals. March
152013;Available at: https://ods.od.nih.gov/fact-sheets/Valerian-HealthProfessional/. Accessed September 11, 2015
- Santos MS, Ferreira F, Cunha AP, et al. An aqueous extract of valerian influences the transport of GABA in synaptosomes. Planta Medica 1994;60:278–279.
- Stevinson C, Ernst E. Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Med 2000;1:91–99.
- Morin CM, Koetter U, Bastien C, et al. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep 2005;28:1465–1471.
- Salter S, Brownie S. Treating primary insomnia: the efficacy of valerian and hops. Aust Fam Physician 2010;39:433–437.
- Ziegler G, Ploch M, Miettinen-Baumann A, Collet W. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia: a randomized, double-blind, comparative clinical study. Eur J Med Res 2002;7:480–486.
- Bent S, Padula A, Moore D, et al. Valerian for sleep: a systematic review and meta-analysis. Am J Med 2006;119:1005–1012.
- Singh YN. Kava: an overview. J Ethnopharmacol 1992;37:13–45.
- Attele AS, Xie J-T, Yuan C-S. Treatment of insomnia: an alternative approach. Altern Med Rev 2000;5:249–259.
- Food and Drug Administration. Consumer advisory: kava-containing dietary supplements may be associated with severe liver injury June
42014;Available at: https://www.fda.gov/Food/ResourcesForYou/Consumers/ucm085482.htm. Accessed September 3, 2015
- DailyMed. U.S. National Library of Medicine. Available at: https://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed August 4, 2015
- Red Book Online Ann Arbor, Michigan: Truven Health Analytics.
2012–2015Available at: http://www.micromedexsolutions.com. Accessed October 15, 2015